|Bid||0.8000 x 3100|
|Ask||0.8335 x 3000|
|Day's range||0.8092 - 0.8600|
|52-week range||0.3650 - 6.0400|
|Beta (5Y monthly)||0.88|
|PE ratio (TTM)||2.90|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.